Loomis Sayles & CO L P Replimune Group, Inc. Transaction History

Loomis Sayles & CO L P

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$15.96 - $22.18 $1.65 Million - $2.29 Million	103,223 Added 8.69%	1,290,450 $22.1 Million
Q2 2023 Aug 11, 2023	BUY	$15.65 - $24.1 $3.58 Million - $5.51 Million	228,561 Added 23.84%	1,187,227 $27.6 Million
Q1 2023 May 11, 2023	BUY	$17.48 - $29.09 $16.8 Million - $27.9 Million	958,666 New	958,666 $16.9 Million
Q1 2022 May 13, 2022	SELL	$15.24 - $29.75 $16.9 Million - $33 Million	-1,108,869 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$25.43 - $34.25 $691,619 - $931,497	-27,197 Reduced 2.39%	1,108,869 $30.1 Million
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $4.16 Million - $5.67 Million	143,473 Added 14.45%	1,136,066 $33.7 Million
Q2 2021 Aug 13, 2021	BUY	$28.5 - $39.37 $6.14 Million - $8.48 Million	215,411 Added 27.72%	992,593 $38.1 Million
Q1 2021 May 17, 2021	BUY	$30.22 - $45.57 $23.5 Million - $35.4 Million	777,182 New	777,182 $23.7 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $694M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.